Amanda Iglesias

Dr. Amanda Iglesias

CIBER (Centro de Investigación Biomédica en Red) enfermedades respiratorias (CIBERES), Instituto de Salud Carlos III, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2009 in Thorax
Verified
Journal Article
Open access
PDF file
Borja G CosíoBorja G Cosío
Borja G Cosío
AIAmanda Iglesias
Amanda Iglesias
ARA Rios
A Rios
ANA Noguera
A Noguera
ESE Sala
E Sala
AAA Agusti
A Agusti
Background: Chronic obstructive pulmonary disease (COPD) is characterised by an abnormal inflammatory response mainly to cigarette smoke that flares up during exacerbations of the disease (ECOPD). Reduced activity of histone deacetylases (HDAC) contributes to enhanced inflammation in stable COPD. It was hypothesised that HDAC activity is further reduced during ECOPD and that theophylline, an HDAC activator, potentiates the anti-inflammatory effect of steroids in these patients. A study was performed to investigate HDAC activity during ECOPD and the effects of theophylline on the anti-inflammatory effects of steroids in a randomised single-blind controlled study. Methods: 35 patients hospitalised with ECOPD and treated according to international guidelines (including systemic steroids) were randomised to receive or not to receive low-dose oral theophylline (100 mg twice daily). Before treatment and 3 months after discharge, HDAC and nuclear factor-κB (NF-κB) activity in sputum macrophages, the concentration of nitric oxide in exhaled air (eNO) and total antioxidant status (TAS), tumour necrosis factor α (TNFα), interleukin (IL)-6 and IL8 levels in sputum supernatants were measured. Results: Patients receiving standard therapy showed decreased NF-κB activity, eNO concentration and sputum levels of TNFα, IL6 and IL8, as well as increased TAS during recovery of ECOPD, but HDAC activity did not change. The addition of low-dose theophylline increased HDAC activity and further reduced IL8 and TNFα concentrations. Conclusions: During ECOPD, low-dose theophylline increases HDAC activity and improves the anti-inflammatory effects of steroids. Trial registration number: NCT00671151

15 September 2015 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
FPFrancesca Polverino
Francesca Polverino
Borja G CosíoBorja G Cosío
Borja G Cosío
JPJaime Pons
Jaime Pons
MLMaria Laucho-Contreras
Maria Laucho-Contreras
PTPaula Tejera
Paula Tejera
COCaroline A. Owen
Caroline A. Owen
Rationale: Patients with chronic obstructive pulmonary disease (COPD) have increased pulmonary lymphoid follicle (LF) counts. B cell–activating factor of tumor necrosis factor family (BAFF) regulates B cells in health, but its role in COPD pathogenesis is unclear. Objectives: To determine whether BAFF expression in pulmonary LFs correlates with COPD severity, LF size or number, and/or readouts of B-cell function in LFs. Methods: We correlated BAFF immunostaining in LFs in lung explants or biopsies from nonsmoking control subjects (NSC), smokers without COPD (SC), and patients with COPD with the number and size of LFs, and LF B-cell apoptosis, activation, and proliferation. We analyzed serum BAFF levels and BAFF expression in B cells in blood and bronchoalveolar lavage samples from the same subject groups. We assessed whether: (1) cigarette smoke extract (CSE) increases B-cell BAFF expression and (2) recombinant BAFF (rBAFF) rescues B cells from CSE-induced apoptosis by inhibiting activation of nuclear factor-κB (NF-κB). Measurements and Main Results: Patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV COPD had increased numbers and larger pulmonary LFs than patients with GOLD stages I–II COPD and SC. We identified two main types of pulmonary LFs: (1) type A, the predominant type in GOLD stages I–II COPD and SC, characterized by abundant apoptotic but few BAFF-positive cells (mostly B cells); and (2) type B, the main type in GOLD stage IV COPD, characterized by abundant BAFF-positive cells but few apoptotic cells (mostly B cells). BAFF levels were also higher in blood and bronchoalveolar lavage B cells in patients with COPD versus NSC and SC. Surprisingly, rBAFF blocked CSE-induced B-cell apoptosis by inhibiting CSE-induced NF-κB activation. Conclusions: Our data support the hypothesis that B-cell BAFF expression creates a self-perpetuating loop contributing to COPD progression by promoting pulmonary B-cell survival and LF expansion.

1 April 2011 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
AKAna L. Kersul
Ana L. Kersul
AIAmanda Iglesias
Amanda Iglesias
ÁRÁngel Ríos
Ángel Ríos
ANAina Noguera
Aina Noguera
AFAina Forteza
Aina Forteza
Borja G CosíoBorja G Cosío
Borja G Cosío

8 December 2013 in HIV Medicine
Verified
Journal Article
Closed access
PDF file
GSG Sampériz
G Sampériz
DGD Guerrero
D Guerrero
MLM López
M López
JVJl Valera
Jl Valera
AIAmanda Iglesias
Amanda Iglesias
AAAlvar Agustí
Alvar Agustí

1 February 2018 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
LLLuis Pérez de Llano
Luis Pérez de Llano
Borja G CosíoBorja G Cosío
Borja G Cosío
AIAmanda Iglesias
Amanda Iglesias
NCNatividad de Las Cuevas
Natividad de Las Cuevas
JSJuan Jose Soler-Cataluña
Juan Jose Soler-Cataluña
IBIrina Bobolea
Irina Bobolea
Introduction: The asthma–chronic obstructive pulmonary disease (COPD) overlap (ACO) is a clinical condition that combines features of those two diseases, and that is difficult to define due to the lack of understanding of the underlying mechanisms. Determining systemic mediators may help clarify the nature of inflammation in patients with ACO. Objectives: We aimed at investigating the role and interaction of common markers of systemic inflammation (IL-6, IL-8, and tumor necrosis factor-α), Th2-related markers (periostin, IL-5, and IL-13), and IL-17 in asthma, COPD, and ACO. Methods: This is a cross-sectional study of patients aged ≥40 years with a post-bronchodilator forced expiratory volume in the first second/forced vital capacity 10 pack-years in a patient with a previous diagnosis of asthma or by the presence of eosinophilia in a patient with a previous diagnosis of COPD. Clinical, functional, and inflammatory parameters were compared between categories using discriminant and network analysis. Results: In total, 109 ACO, 89 COPD, and 94 asthma patients were included. Serum levels (median [interquartile range]) of IL-5 were higher in asthma patients than in COPD patients (2.09 [0.61–3.57] vs 1.11 [0.12–2.42] pg/mL, respectively; p=0.03), and IL-8 levels (median [interquartile range]) were higher in COPD patients than in asthma patients (9.45 [6.61–13.12] vs 7.03 [4.69–10.44] pg/mL, respectively; p<0.001). Their values in ACO were intermediate between those in asthma and in COPD. Principal component and network analysis showed a mixed inflammatory pattern in ACO in between asthma and COPD. IL-13 was the most connected node in the network, with different weights among the three conditions. Conclusion: Asthma and COPD are two different inflammatory conditions that may overlap in some patients, leading to a mixed inflammatory pattern. IL-13 could be central to the regulation of inflammation in these conditions.

1 July 2016 in Chest
Verified
Journal Article
Closed access
Borja G CosíoBorja G Cosío
Borja G Cosío
HSHanaa Shafiek
Hanaa Shafiek
AIAmanda Iglesias
Amanda Iglesias
Aina M YañezAina M Yañez
Aina M Yañez
RCRocío Córdova
Rocío Córdova
AAAlvar Agusti
Alvar Agusti